Precision Biosensor

Precision Biosensor Current Assets

The Current Assets of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is 8.87 B KRW. In the previous year, Current Assets was 16.11 B KRW — a change of -44.93% (lower).

Current Assets

8.87 BKRW

YoY

-44.93%

Last updated:

Current Assets of Precision Biosensor is 2025 8.87 B KRW. Current Assets of Precision Biosensor was 2024 16.11 B KRW. It decreases by -44.93% lower compared to the previous year.

The Precision Biosensor Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
6.23 B KRW
Jan 1, 2019
14.98 B KRW
Jan 1, 2020
32.33 B KRW
Jan 1, 2021
33.02 B KRW
Jan 1, 2022
20.66 B KRW
Jan 1, 2023
18.17 B KRW
Jan 1, 2024
16.11 B KRW
Jan 1, 2025
8.87 B KRW
The Precision Biosensor Current Assets history
YEARCurrent AssetsYoY
8.87 BKRW-44.93%
16.11 BKRW-11.33%
18.17 BKRW-12.05%
20.66 BKRW-37.43%
33.02 BKRW+2.13%
32.33 BKRW+115.79%
14.98 BKRW+140.48%
6.23 BKRW-32.62%
9.25 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Current Assets of Precision Biosensor is 8.87 B KRW in 2025.

Current Assets of Precision Biosensor changed from 16.11 B KRW to 8.87 B KRW, representing a -44.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Precision Biosensor historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Precision Biosensor

All Key Metrics — Precision Biosensor